AURA vs KURA
AURA: Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving organ function. KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
Side-by-side fundamentals
| Metric | AURA | KURA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $7.16 | $10.15 | |
| Market cap as of 2026-07-29 | $740M | $830M | |
| PEG as of 2026-07-29 | n/a | -0.05 | |
| Net margin as of 2026-07-29 | n/a | -411.2% | |
| Gross margin as of 2026-07-29 | n/a | +99.9% | |
| Operating margin as of 2026-07-29 | n/a | -443.5% | |
| ROE as of 2026-07-29 | -78.1% | -141.9% | AURA higher |
| ROA as of 2026-07-29 | -64.1% | -43.3% | KURA higher |
| Debt / equity as of 2026-07-29 | 0.00 | 0.09 | AURA lower |
| Revenue growth (YoY) as of 2026-07-29 | n/a | +29.5% | |
| Beta as of 2026-07-29 | 0.40 | 0.38 | |
| 1-year return as of 2026-07-27 close | -1.0% | +62.9% | KURA higher |
Fundamentals: market data, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.